Thus, the increase of LAP+ Tregs in the peripheral blood of CRC patients could reflect the increase of LAP+ Tregs in tumor tissues and could be correlated with the cancer stage, suggesting that the size of peripheral blood LAP-positive CD4+Foxp3+ T cell subpopulation can serve as a surrogate marker for the immunosuppression process in CRC. The gene discussed is FOXP3; the disease is colorectal carcinoma.